Immune responses linked to severe dengue in children (primary infection)
Official title: Immune responses associated with severe disease in patients with primary dengue infection
Funded at Emory University · NIH-11596504 · Data updated 2026-11-12
This grant studies why some kids get very sick from their first dengue infection and how their immune system reacts differently from secondary infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 10, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $29,279 |
| NIH project number | 3R01AI186371-03S1 |
| Project ID | NIH-11596504 on NIH RePORTER |
Who could benefit from this research
✓Could help
Pediatric patients with confirmed dengue infection, particularly those experiencing severe disease.
✕Less likely to help
Children with mild dengue who recover quickly may not benefit from the specific immune comparisons.
What this research studies
The project follows children with dengue to compare their innate immune responses, dengue-specific antibodies, and T cell activity during severe primary dengue versus severe secondary dengue. Researchers will use patient samples from India to analyze differences in immune signals, antibody quality, and T cell behavior that may explain why primary infections can be more dangerous in some cases. The study aims to tie these immune patterns to disease severity and identify markers that could guide better care. Results could help doctors predict who is at risk and inform future treatments or vaccines for pediatric patients.
Why it matters
Potential benefit: Understanding these immune differences could lead to better risk prediction and targeted interventions for children with dengue.
How similar studies have gone: Prior work has shown distinct immune responses in severe dengue; this study extends comparisons to primary versus secondary severe cases.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Kaja, Murali Krishna — Emory University
- Study coordinator: Kaja, Murali Krishna
Related research
Other NIH-funded projects on the same topics.
-
Phase 2b trial of dengue vaccines TAK-003 and Butantan-DV to boost lasting, broad antibody protection
A trial tests whether giving a second dengue vaccine (Butantan-DV) after an initial TAK-003 shot can create stronger, longer-lasting antibodies that work against all dengue types.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Selective GAK inhibitors to fight dengue, VEEV and other emerging viral infections
A Stanford team is testing new, selective inhibitors of GAK to block how certain viruses enter and exit cells, with the goal of a broad antiviral approach that could help people exposed to dengue, VEEV, and similar infections.
-
Defining immune markers predicting protection against dengue in a long-term family study in Thailand
This grant looks at how antibodies develop to protect against dengue in children from a long-running family cohort in Thailand, with the goal of identifying immune signs that predict protection across multiple dengue serotypes.
-
Understanding dengue protection in children from a long-term Thai family cohort
A long-term study in Thailand follows families to understand how early exposures to dengue shape protection and illness risk for children as they encounter the virus over time.
-
A T cell vaccine approach to prevent Dengue and Zika infections
A new vaccine approach aims to teach the immune system’s T cells to recognize and fight Dengue and Zika viruses without triggering harmful antibody responses.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.